switching between glp-1 agonists ada #4 NN Clinical Use Treatment discontinuation among users of

Obesity as a Public Health Crisis and Contemporary Therapies Between 2021 and 2023, the prevalence of obesity, defined as a body-mass index (BMI, weight in kilograms divided by square of height in meters) 30, in adults in the United States increased to 40.3%, with no significant differences between men and women [6]

The SELECT trial was the first large, randomized study to show that a drug used for obesity could reduce cardiovascular disease, says Isaacs

GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy

Most people are underhydrated to begin with, and appetite suppression can make it even easier to forget to drink fluids

Many people wonder if they can obtain GLP-1 (glucagon-like peptide-1) directly from foods, especially given the popularity of GLP-1 medications like Ozempic and Wegovy for diabetes and weight management

Although the mechanisms leading to a blood pressure decrease during the treatment with GLP-1 agonists have not been fully elucidated it could be the result of an increased sodium and water excretion and/or inhibition of the RAAS activity 14